Conv. Plasma
Nigella Sativa

All remdesivir studies
Meta analysis
study COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -62% Improvement Relative Risk Remdesivir for COVID-19  Ho et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 26,445 patients in the USA (January 2020 - August 2021) Higher mortality with remdesivir (p<0.000001) Ho et al., HCA Healthcare J. Medicine, Oct 2023 Favors remdesivir Favors control

A Retrospective Cohort Study Assessing the Impact of Statin Therapy on Hospital Length of Stay and Inpatient Mortality in COVID-19 Patients

Ho et al., HCA Healthcare Journal of Medicine, doi:10.36518/2689-0216.1546
Oct 2023  
  Source   PDF   All   Meta
Retrospective 26,445 hospitalized COVID-19 patients in the USA, showing higher mortality with remdesivir.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 62.0% higher, OR 1.62, p < 0.001, treatment 5,294, control 21,151, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ho et al., 31 Oct 2023, retrospective, USA, peer-reviewed, 9 authors, study period 1 January, 2020 - 31 August, 2021.
This PaperRemdesivirAll
A Retrospective Cohort Study Assessing the Impact of Statin Therapy on Hospital Length of Stay and Inpatient Mortality in COVID-19 Patients
DO Huy V Ho, DO Hamish Patel, MD Mohammed Ahmed, MD Ahmed Eddib, MD Fagunkumar Modi, MD Domenick Sorresso, PhD Rahul Mhaskar, David Phrathep, MD Olugbenga Oyesanmi
HCA Healthcare Journal of Medicine, doi:10.36518/2689-0216.1546
Background Coronaviruses, known for their crown-like appearance, cause mild gastrointestinal and respiratory diseases. Some cause outbreaks of respiratory diseases, most recently, SARS-CoV-2, the coronavirus disease 2019 (COVID-19). Individuals with COVID-19 are reported to be in both arterial and venous prothrombotic states. In addition to a lipid-lowering effect, statin also has an anti-inflammatory effect, which addresses one of the underlying causes of thrombosis. An in-silico study revealed that statins could directly interact with the main protease enzyme of SARS-CoV-2 and prevent infectivity. Due to these pleiotropic properties, statins may positively impact the outcome of hospitalized patients with COVID-19 infections. Methods A total of 26 445 acute COVID-19-infected patients were included in this study. Patients were stratified based on home statin use status: no statins, high-intensity statins (atorvastatin 40-80 mg daily and rosuvastatin 20-40 mg daily), and low-to-moderate intensity statins (all other statins). A multivariate generalized linear model and logistic regression were used to predict the hospital length of stay and inpatient mortality, respectively. Results The hospital length of stay was compared between low-intensity and high-intensity statin use against no statin therapy. The length of stay was 3.88 days (95% CI, 3.56-4.20; P < .0001) longer among patients with low-dose statin therapy compared to patients without. The length of stay was 4.77 days (95% CI, 4.42-5.13; P <.0001) longer among patients with high-intensity statin therapy than those without. The odds of in-hospital mortality decreased by 24% (OR, 0.76; 95% CI, 0.76-0.97) among those with high-dose statin therapy compared to patients without (P = .02). There was no statistical significance between the low-dose statin group and the no statin group for inpatient mortality. Conclusion Hospitalized COVID-19 patients on statin therapy, regardless of intensity, are more likely to have a longer length of stay. There may be a mortality benefit in using high-intensity statin in acute COVID-19-infected patients. The results of this study are insufficient to recommend statin therapy for inpatient COVID-19 treatment. However, patients with significant cardiovascular comorbidities, where statins are indicated, should be on these medications, especially amidst the COVID-19 pandemic. Randomized controlled trials are needed to assess the potential in-hospital benefit of statin therapy on COVID-19 patients.
Conflicts of Interest The authors declare they have no conflicts of interest. Drs Ahmed, Eddib, Ho, and Modi are employees of HCA Florida Citrus Hospital, a hospital affiliated with the journal's publisher. Drs Patel and Sorresso are employees of HCA Florida Bayonet Point Hospital, a hospital affiliated with the journal's publisher. Dr Oyesanmi is an employee of HCA Healthcare/USF Morsani College of Medicine Graduate Medical Education, an organization affiliated with the journal's publisher. This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare-affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities. Author Affiliations
Abou-Ismail, Diamond, Kapoor, Arafah, Nayak, The hypercoagulable state in COVID-19: incidence, pathophysiology, and management, Thromb Res, doi:10.1016/j.throm-res.2020.06.02
Cheung, Hung, Chan, Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis, Gastroenterology, doi:10.1053/j.gastro.2020.03.065
Chow, Im, Chiu, The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis, PLoS One, doi:10.1371/journal.pone.0253576
Ctt) Collaboration ; Baigent, Blackwell, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, doi:10.1016/S0140-6736(10)61350-5
Darif, Hammi, Kihel, Idrissi Saik, Guessous et al., The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong?, Microb Pathog, doi:10.1016/j.micpath.2021.104799
De Luca, Debel, Cercek, Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: insights from the ISACS STEMI COVID 19 registry, Atherosclerosis, doi:10.1016/j.atherosclerosis.2021.06.926
Katsoularis, Fonseca-Rodríguez, Farrington, Lindmark, Connolly, Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study, Lancet, doi:10.1016/S0140-6736(21)00896-5
Larosa, Grundy, Waters, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, doi:10.1056/NEJ-Moa050461
Lefer, Statins as potent antiinflammatory drugs, Circulation, doi:10.1161/01.cir.0000033635.42612
Morawska, Milton, It is time to address airborne transmission of coronavirus disease 2019 (COVID-19), Clin Infect Dis, doi:10.1093/cid/ciaa939
Schartl, Bocksch, Koschyk, Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease, Circulation, doi:10.1161/hc2901.093188
Umakanthan, Senthil, John, The protective role of statins in COVID-19 patients: a retrospective observational study, Transl Med Commun, doi:10.1186/s41231-021-00102-4
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop